Next Article in Journal
Efficiently Classifying Lung Sounds through Depthwise Separable CNN Models with Fused STFT and MFCC Features
Next Article in Special Issue
Atypical Ductal Hyperplasia after Vacuum-Assisted Breast Biopsy: Can We Reduce the Upgrade to Breast Cancer to an Acceptable Rate?
Previous Article in Journal
Presence of SARS-CoV-2 Nucleoprotein in Cardiac Tissues of Donors with Negative COVID-19 Molecular Tests
Previous Article in Special Issue
Unilateral Orbital Metastasis as the Unique Symptom in the Onset of Breast Cancer in a Postmenopausal Woman: Case Report and Review of the Literature
 
 
Article

Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting

1
Department of Obstetrics and Gynecology and CCC Munich LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany
2
Department of Internal Medicine III and CCC Munich LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany
3
Institute of Pathology and CCC Munich LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany
4
Gynecologic Oncology Center and CCC Munich LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany
5
Breast Center and CCC Munich LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Mauro G. Mastropasqua
Diagnostics 2021, 11(4), 733; https://doi.org/10.3390/diagnostics11040733
Received: 2 March 2021 / Revised: 7 April 2021 / Accepted: 13 April 2021 / Published: 20 April 2021
(This article belongs to the Special Issue Challenging Topics in Breast Cancer Diagnosis and Treatment)
The advent of molecular diagnostics and the rising number of targeted therapies have facilitated development of precision oncology for cancer patients. In order to demonstrate its impact for patients with metastatic breast cancer (mBC), we initiated a Molecular Tumor Board (MTB) to provide treatment recommendations for mBC patients who had disease progression under standard treatment. NGS (next generation sequencing) was carried out using the Oncomine multi-gene panel testing system (Ion Torrent). The MTB reviewed molecular diagnostics’ results, relevant tumor characteristics, patient’s course of disease and made personalized treatment and/or diagnostic recommendations for each patient. From May 2017 to December 2019, 100 mBC patients were discussed by the local MTB. A total 72% of the mBC tumors had at least one molecular alteration (median 2 per case, range: 1 to 6). The most frequent genetic changes were found in the following genes: PIK3CA (19%) and TP53 (17%). The MTB rated 53% of these alterations as actionable and treatment recommendations were made accordingly for 49 (49%) patients. Sixteen patients (16%) underwent the suggested therapy. Nine out of sixteen patients (56%; 9% of all) experienced a clinical benefit with a progression-free survival ratio ≥ 1.3. Personalized targeted therapy recommendations resulting from MTB case discussions could provide substantial benefits for patients with mBC and should be implemented for all suitable patients. View Full-Text
Keywords: precision oncology; personalized medicine; metastatic breast cancer; molecular tumor board; molecular diagnostics precision oncology; personalized medicine; metastatic breast cancer; molecular tumor board; molecular diagnostics
Show Figures

Figure 1

MDPI and ACS Style

Sultova, E.; Westphalen, C.B.; Jung, A.; Kumbrink, J.; Kirchner, T.; Mayr, D.; Rudelius, M.; Ormanns, S.; Heinemann, V.; Metzeler, K.H.; Greif, P.A.; Hester, A.; Mahner, S.; Harbeck, N.; Wuerstlein, R. Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. Diagnostics 2021, 11, 733. https://doi.org/10.3390/diagnostics11040733

AMA Style

Sultova E, Westphalen CB, Jung A, Kumbrink J, Kirchner T, Mayr D, Rudelius M, Ormanns S, Heinemann V, Metzeler KH, Greif PA, Hester A, Mahner S, Harbeck N, Wuerstlein R. Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. Diagnostics. 2021; 11(4):733. https://doi.org/10.3390/diagnostics11040733

Chicago/Turabian Style

Sultova, Elena, C. Benedikt Westphalen, Andreas Jung, Joerg Kumbrink, Thomas Kirchner, Doris Mayr, Martina Rudelius, Steffen Ormanns, Volker Heinemann, Klaus H. Metzeler, Philipp A. Greif, Anna Hester, Sven Mahner, Nadia Harbeck, and Rachel Wuerstlein. 2021. "Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting" Diagnostics 11, no. 4: 733. https://doi.org/10.3390/diagnostics11040733

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop